Cardiff Oncology, Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-01-02

Reporting Person: Erlander Mark (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-02	Common Stock	M	260	—	Acquired	13629	Direct
2021-01-02	Common Stock	F	113	—	Disposed	13516	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-02	Restricted Stock Units	$	M	260	Disposed		Common Stock (260.0)	Direct

Footnotes

F1: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017.

F2: The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 113 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021.

F3: Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock.

F4: On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4.